;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • CPP-115: Phase I started

    Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla. Product: CPP-115 Business: Neurology Molecular target: GABA transaminase Description: GABA transaminase inhibitor Indication: Treat West syndrome (…

    Published on 9/8/2014
  • CPX-351: Phase II started

    Celator Pharmaceuticals Inc. (NASDAQ:CPXX), Ewing, N.J. Product: CPX-351 Business: Cancer Molecular target: DNA polymerase; Topoisomerase II (TOP2) Description: Liposomal formulation of cytarabine and daunorubicin …

    Published on 9/8/2014
  • Ipafricept: Phase Ib ongoing

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Ipafricept (Fzd8-Fc) (OMP-54F28) Business: Cancer Molecular target: NA Description: Wnt signaling antagonist Indication: Treat cancer Endpoint: …

    Published on 9/8/2014
  • LuViva Advanced Cervical Scan: Postmarketing study started

    Guided Therapeutics Inc. (OTCBB:GTHP), Norcross, Ga. Product: LuViva Advanced Cervical Scan (formerly LightTouch Cervical Scanner) Business: Diagnostic Molecular target: NA Description: Non-invasive cervical cancer test…

    Published on 9/8/2014
  • MSRX-110: Phase I/II started

    MonoSol Rx LLC, Warren, N.J. Product: MSRX-110 Business: Endocrine/Metabolic Molecular target: NA Description: Testosterone replacement delivered via PharmFilm oral film Indication: Treat hpogonadism Endpoint: …

    Published on 9/8/2014
  • Topsalysin: Completed Phase III enrollment

    Sophiris Bio Inc. (NASDAQ:SPHS), La Jolla, Calif. Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Topsalysin (PORxin) (PRX302) (formerly PSA-PAH1) Business: Genitourinary Molecular target: …

    Published on 9/8/2014
  • Alisporivir: Phase I started

    Debiopharm Group, Lausanne, Switzerland Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Alisporivir (Debio 025, DEB025) Business: Infectious Molecular target: Cyclophilin Description: Oligopeptide …

    Published on 9/1/2014
  • AlloMap Molecular Expression Test: Clinical trial started

    CareDx Inc. (NASDAQ:CDNA), Brisbane, Calif. Product: AlloMap Molecular Expression Test Business: Diagnostic Molecular target: NA Description: Non-invasive multi-gene expression profiling blood diagnostic Indication: …

    Published on 9/1/2014
  • Ampion: Phase III ongoing

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide cleaved from…

    Published on 9/1/2014
  • BioChaperone PDGF-BB: Phase III started

    Adocia S.A. (Euronext:ADOC), Lyon, France Product: BioChaperone PDGF-BB Business: Dermatology Molecular target: Platelet derived growth factor BB (PDGFBB) Description: Recombinant platelet derived growth factor BB (…

    Published on 9/1/2014
  • Bosulif bosutinib: Phase III started

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Avillion LLP, London, U.K. Product: Bosulif bosutinib (SKI-606, PF-5208763, PF-05208763) Business: Cancer Molecular target: BCR-ABL tyrosine kinase; Src Description: Dual inhibitor…

    Published on 9/1/2014
  • Brilacidin: Completed Phase IIb enrollment

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin (formerly PMX-30063) Business: Infectious Molecular target: NA Description: Synthetic defensin mimetic bactericidal antibiotic Indication: Treat acute …

    Published on 9/1/2014
  • BTI-320: Completed Phase IIb enrollment

    Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H. Product: BTI-320 (formerly PAZ320) Business: Endocrine/Metabolic Molecular target: NA Description: Chewable polysaccharide that inhibits alpha glucosidase …

    Published on 9/1/2014
  • DAG for Injection: Phase I/II amended

    DelMar Pharmaceuticals Inc. (OTCBB:DMPI), Vancouver, B.C. Guangxi Wuzhou Zhongheng Group Co. Ltd. (Shanghai:600252), Wuzhou, China Product: DAG for Injection (VAL-083) Business: Cancer Molecular target: DNA Description:…

    Published on 9/1/2014
  • Dutetrabenazine: Completed Phase III enrollment

    Auspex Pharmaceuticals Inc. (NASDAQ:ASPX), La Jolla, Calif. Product: Dutetrabenazine (SD-809) Business: Neurology Molecular target: Vesicular monoamine transporter 2 (VMAT2) (SLC18A2) Description: Deuterium-substituted …

    Published on 9/1/2014
  • Eculizumab: Phase II/III started

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: Eculizumab (Soliris) Business: Transplant Molecular target: Complement 5 (C5) Description: Humanized mAb targeting complement 5 (C5) Indication: …

    Published on 9/1/2014
  • EDP-239: Phase I

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: EDP-239 Business: Infectious Molecular target: HCV NS5A protein Description: HCV NS5A protein …

    Published on 9/1/2014
  • HMPL-004: Phase III discontinued

    Hutchison China MediTech Ltd. (LSE:HCM), Hong Kong, China Nestle S.A. (SIX:NESN), Vevey, Switzerland Product: HMPL-004 Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha; Interleukin-1 (IL-1) beta …

    Published on 9/1/2014
  • ISIS-APOCIIIRx: Phase III started

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-APOCIIIRx (ISIS 304801) Business: Endocrine/Metabolic Molecular target: Apolipoprotein C-III (APOCIII) (APOC3) Description: Apolipoprotein C-III (…

    Published on 9/1/2014
  • Loteprednol etabonate mucosal penetrating particle: Phase II started

    Kala Pharmaceuticals Inc., Waltham, Mass. Product: Loteprednol etabonate mucosal penetrating particle, LE-MPP (KPI-121) Business: Ophthalmic Molecular target: NA Description: Loteprednol etabonate, a steroid, delivered …

    Published on 9/1/2014
  • Metadoxine ER: Phase IIb started

    Alcobra Ltd. (NASDAQ:ADHD), Tel Aviv, Israel Product: Metadoxine ER (MDX) (MG01CI) Business: Neurology Molecular target: Serotonin (5-HT2B) receptor Description: Extended-release formulation of metadoxine, a selective …

    Published on 9/1/2014
  • MMI-0100: Phase I started

    Moerae Matrix Inc., Morristown, N.J. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: MMI-0100 Business: Pulmonary Molecular target: MAP kinase-activated protein kinase 2 (MAPKAPK2) (MK2) …

    Published on 9/1/2014
  • MRX6: Phase II started

    Celsus Therapeutics plc (NASDAQ:CLTX), London, U.K. Product: MRX6, MRX-6 Business: Dermatology Molecular target: Phospholipase A2 (PLA2) Description: Topical multifunctional anti-inflammatory compound that inhibits …

    Published on 9/1/2014
  • Mydicar: Phase II started

    AmpliPhi Biosciences Corp. (OTCBB:APHB), Richmond, Va. Celladon Corp. (NASDAQ:CLDN), San Diego, Calif. Product: Mydicar (AAV1/SERCA2a) Business: Cardiovascular Molecular target: ATPase Ca++ transporting cardiac muscle …

    Published on 9/1/2014
  • NormoCort: Phase III started

    Cortendo AB, Gothenburg, Sweden Product: NormoCort (COR-003) Business: Other Molecular target: Cytochrome P450 family 11 subfamily B polypeptide 1 (CYP11B1); Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (…

    Published on 9/1/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993